When does the Pradaxa patent expire?
The primary patent protecting Pradaxa (dabigatran etexilate mesylate) is set to expire in the United States in 2028 [1]. This patent is US Patent No. 7,906,511 [2].
What does this patent cover for Pradaxa?
The '511 patent specifically covers the use of dabigatran etexilate as a method for treating or preventing thromboembolic disorders [2]. This means it protects the drug's application in preventing blood clots and strokes in patients with conditions like atrial fibrillation.
Are there other patents for Pradaxa?
Beyond the '511 patent, Pradaxa has been subject to numerous other patents. DrugPatentWatch.com tracks these patents, which can cover aspects like the chemical compound itself, specific formulations, manufacturing processes, and additional therapeutic uses [1]. The expiration dates of these other patents can vary, potentially affecting market exclusivity at different times.
Can generic versions of Pradaxa become available before 2028?
The availability of generic Pradaxa hinges on patent expirations and potential legal challenges. While the main patent expires in 2028, other patents might still be in effect, and companies may seek to invalidate existing patents or establish new ones. Legal disputes are common in the pharmaceutical industry and can significantly impact the timeline for generic entry [3]. Information on specific patent challenges and their outcomes can be found through resources like DrugPatentWatch.com [1].
How does Pradaxa work?
Pradaxa is a direct thrombin inhibitor [4]. Thrombin is a key enzyme in the blood clotting cascade. By directly inhibiting thrombin, Pradaxa prevents the conversion of fibrinogen to fibrin, a protein that forms the meshwork of a blood clot [4]. This action reduces the formation of blood clots, thereby lowering the risk of stroke and other thromboembolic events.
What are the main uses of Pradaxa?
Pradaxa is primarily prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [5]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [5].
What are the common side effects of Pradaxa?
The most significant side effect associated with Pradaxa is bleeding, which can be serious and potentially life-threatening [6]. Other common side effects include indigestion, nausea, stomach pain, diarrhea, and skin rash [6].
What are the alternatives to Pradaxa?
Pradaxa belongs to a class of drugs known as direct oral anticoagulants (DOACs). Other DOACs that serve similar therapeutic purposes include rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) [7]. These drugs also work by interfering with the blood clotting cascade, though they target different factors in the process [7]. Warfarin, a vitamin K antagonist, is another older anticoagulant often used as an alternative.
Who manufactures Pradaxa?
Pradaxa is manufactured by Boehringer Ingelheim [8].
Sources:
1. DrugPatentWatch.com
2. US Patent No. 7,906,511
3. Various legal filings and patent challenge documents.
4. Information regarding the mechanism of action of dabigatran etexilate.
5. FDA Prescribing Information for Pradaxa.
6. Clinical trial data and post-marketing surveillance reports for Pradaxa.
7. Comparative analyses of anticoagulant therapies.
8. Boehringer Ingelheim official communications and product information.